We hereby attach the Annual report for the financial year 2024-25
LOTUSEYE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.5 pts more than Nifty Microcap 250 and 9.7 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lotus Eye Hospital has filed its 28th Annual Report for the financial year ending 31st March 2025. Revenue from operations grew modestly from Rs 49.51 crores to Rs 50.86 crores, an increase of about 2.7%. However, profit after tax dropped sharply from Rs 2.91 crores to Rs 0.74 crores, a fall of roughly 75%, largely because the company expanded by opening its 9th centre at Karur and invested Rs 5.57 crores in new capital assets. Expenses rose from Rs 45.50 crores to Rs 49.49 crores, which weighed on margins. The company is net debt-free with cash and equivalents of Rs 2.01 crores, paid-up equity capital stands at Rs 20.80 crores, and no dividend has been declared for the year.
Shareholders see weak bottom-line performance despite steady top-line growth, as expansion costs have eaten into profits. The lack of dividend and sharp earnings decline may put pressure on the stock in the short term, though the new Karur centre could support future growth once it stabilises.